{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T02:57:23Z","timestamp":1693709843868},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1097\/hpc.0b013e318292f168","type":"journal-article","created":{"date-parts":[[2013,7,27]],"date-time":"2013-07-27T01:11:16Z","timestamp":1374887476000},"page":"141-149","source":"Crossref","is-referenced-by-count":3,"title":["A Comprehensive Acute Coronary Syndrome Algorithm for Centers With Percutaneous Coronary Intervention Capability"],"prefix":"10.1097","volume":"12","author":[{"given":"Michael","family":"McDaniel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Tanveer","family":"Rab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Keadey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Liberman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Fantz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhinav","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aloke","family":"Finn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anwar","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Lowery-North","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kreton","family":"Mavromatis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Habib","family":"Samady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-7-20210126","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1001\/jama.295.16.1912","article-title":"Association between hospital process performance and outcomes among patients with acute coronary syndromes.","volume":"295","author":"Peterson","year":"2006","journal-title":"JAMA"},{"key":"R4-7-20210126","first-page":"e574","article-title":"2011 ACCFAHASCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology FoundationAmerican Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.","volume":"124","author":"Levine","year":"2011","journal-title":"Circulation"},{"key":"R5-7-20210126","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1067\/mem.2000.111057","article-title":"Triage of patients for a rapid (5-minute) electrocardiogram: a rule based on presenting chief complaints.","volume":"36","author":"Graff","year":"2000","journal-title":"Ann Emerg Med"},{"key":"R6-7-20210126","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ahj.2011.10.021","article-title":"Development and validation of a prioritization rule for obtaining an immediate 12-lead electrocardiogram in the emergency department to identify ST-elevation myocardial infarction.","volume":"163","author":"Glickman","year":"2012","journal-title":"Am Heart J"},{"key":"R7-7-20210126","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/HPC.0b013e31826f4e8e","article-title":"Ability of triage decision rules for rapid electrocardiogram to identify patients with suspected ST-elevation myocardial infarction.","volume":"11","author":"Osborne","year":"2012","journal-title":"Crit Pathw Cardiol"},{"key":"R9-7-20210126","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.jacc.2012.06.017","article-title":"Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study.","volume":"60","author":"Romagnoli","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R10-7-20210126","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S0140-6736(11)60404-2","article-title":"RIVAL Trial Group. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial.","volume":"377","author":"Jolly","year":"2011","journal-title":"Lancet"},{"key":"R11-7-20210126","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1016\/j.jacc.2012.07.050","article-title":"RIVAL Investigators. Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation.","volume":"60","author":"Mehta","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R12-7-20210126","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(11)60764-2","article-title":"HORIZONS-AMI Trial Investigators. Heparin plus a glycoprotein IIbIIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial.","volume":"377","author":"Stone","year":"2011","journal-title":"Lancet"},{"key":"R13-7-20210126","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1161\/CIRCULATIONAHA.110.981688","article-title":"Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial Investigators. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction.","volume":"123","author":"Dangas","year":"2011","journal-title":"Circulation"},{"key":"R14-7-20210126","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction.","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"key":"R15-7-20210126","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jacc.2007.04.059","article-title":"Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden.","volume":"50","author":"Sianos","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R16-7-20210126","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM200106213442502","article-title":"TARGET Investigators. Do tirofiban and ReoPro give similar efficacy trial. Comparison of two platelet glycoprotein IIbIIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.","volume":"344","author":"Topol","year":"2001","journal-title":"N Engl J Med"},{"key":"R17-7-20210126","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0002-9149(01)02319-0","article-title":"Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions.","volume":"89","author":"Kabbani","year":"2002","journal-title":"Am J Cardiol"},{"key":"R18-7-20210126","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1001\/jama.299.15.joc80026","article-title":"Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.","volume":"299","author":"Valgimigli","year":"2008","journal-title":"JAMA"},{"key":"R19-7-20210126","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.amjcard.2005.09.080","article-title":"Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIbIIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention.","volume":"97","author":"Danzi","year":"2006","journal-title":"Am J Cardiol"},{"key":"R22-7-20210126","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.jacc.2009.01.053","article-title":"Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis.","volume":"53","author":"De Luca","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R23-7-20210126","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/CIRCINTERVENTIONS.108.847996","article-title":"A comparison of abciximab and small-molecule glycoprotein IIbIIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.","volume":"2","author":"Gurm","year":"2009","journal-title":"Circ Cardiovasc Interv"},{"key":"R24-7-20210126","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"R25-7-20210126","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1161\/01.CIR.0000051362.96946.15","article-title":"Clopidogrel in Unstable angina to prevent Recurrent Events Trial Investigators. Early and late effects of clopidogrel in patients with acute coronary syndromes.","volume":"107","author":"Yusuf","year":"2003","journal-title":"Circulation"},{"key":"R26-7-20210126","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1056\/NEJMoa0901316","article-title":"EARLY ACS Investigators. Early versus delayed, provisional eptifibatide in acute coronary syndromes.","volume":"360","author":"Giugliano","year":"2009","journal-title":"N Engl J Med"},{"key":"R27-7-20210126","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/jama.297.6.591","article-title":"ACUITY Investigators. Routine upstream initiation vs deferred selective use of glycoprotein IIbIIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.","volume":"297","author":"Stone","year":"2007","journal-title":"JAMA"},{"key":"R28-7-20210126","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes.","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"key":"R29-7-20210126","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1093\/eurheartj\/ehm224","article-title":"Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis.","volume":"28","author":"Murphy","year":"2007","journal-title":"Eur Heart J"},{"key":"R30-7-20210126","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jacc.2010.04.023","article-title":"Evidence of pre-procedural statin therapy a meta-analysis of randomized trials.","volume":"56","author":"Winchester","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R31-7-20210126","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jacc.2007.02.025","article-title":"Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.","volume":"49","author":"Patti","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R32-7-20210126","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1016\/j.jacc.2009.09.010","article-title":"TIMI Study Group. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.","volume":"54","author":"Gibson","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R33-7-20210126","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1056\/NEJMoa1109596","article-title":"ISAR-REACT 4 Trial Investigators. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.","volume":"365","author":"Kastrati","year":"2011","journal-title":"N Engl J Med"},{"key":"R34-7-20210126","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.295.13.joc60034","article-title":"Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.","volume":"295","author":"Kastrati","year":"2006","journal-title":"JAMA"},{"key":"R35-7-20210126","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJMoa0802944","article-title":"ISAR-REACT 3 Trial Investigators. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.","volume":"359","author":"Kastrati","year":"2008","journal-title":"N Engl J Med"},{"key":"R36-7-20210126","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/jama.288.3.342","article-title":"Impact of a clinical decision rule on hospital triage of patients with suspected acute cardiac ischemia in the emergency department.","volume":"288","author":"Reilly","year":"2002","journal-title":"JAMA"},{"key":"R37-7-20210126","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1056\/NEJM199606063342303","article-title":"Prediction of the need for intensive care in patients who come to the emergency departments with acute chest pain.","volume":"334","author":"Goldman","year":"1996","journal-title":"N Engl J Med"},{"key":"R39-7-20210126","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM200004203421603","article-title":"Missed diagnoses of acute cardiac ischemia in the emergency department.","volume":"342","author":"Pope","year":"2000","journal-title":"N Engl J Med"},{"key":"R40-7-20210126","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0002-9149(97)00422-0","article-title":"Impact on the care of the emergency department chest pain patient from the chest pain evaluation registry (CHEPER) study.","volume":"80","author":"Graff","year":"1997","journal-title":"Am J Cardiol"},{"key":"R41-7-20210126","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1056\/NEJM199812243392603","article-title":"A clinical trial of a chest-pain observation unit for patients with unstable angina. Chest Pain Evaluation in the Emergency Room (CHEER) Investigators.","volume":"339","author":"Farkouh","year":"1998","journal-title":"N Engl J Med"},{"key":"R42-7-20210126","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.1997.03550200046030","article-title":"Costs of an emergency department-based accelerated diagnostic protocol vs hospitalization in patients with chest pain: a randomized controlled trial.","volume":"278","author":"Roberts","year":"1997","journal-title":"JAMA"},{"key":"R43-7-20210126","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0196-0644(97)70316-0","article-title":"Patient satisfaction with an emergency department chest pain observation unit.","volume":"29","author":"Rydman","year":"1997","journal-title":"Ann Emerg Med"},{"key":"R44-7-20210126","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jama.284.7.835","article-title":"The TIMI risk score for unstable anginanon-ST elevation MI: a method for prognostication and therapeutic decision making.","volume":"284","author":"Antman","year":"2000","journal-title":"JAMA"},{"key":"R46-7-20210126","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1056\/NEJMoa0903515","article-title":"Sensitive troponin I assay in early diagnosis of acute myocardial infarction.","volume":"361","author":"Keller","year":"2009","journal-title":"N Engl J Med"},{"key":"R47-7-20210126","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJMoa0900428","article-title":"Early diagnosis of myocardial infarction with sensitive cardiac troponin assays.","volume":"361","author":"Reichlin","year":"2009","journal-title":"N Engl J Med"},{"key":"R48-7-20210126","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.jacc.2011.11.068","article-title":"GIFT Investigators. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study.","volume":"59","author":"Price","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R49-7-20210126","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"key":"R50-7-20210126","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.111.029165","article-title":"Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: impact on Thrombosis and Safety (GRAVITAS) trial.","volume":"124","author":"Price","year":"2011","journal-title":"Circulation"},{"key":"R51-7-20210126","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/eurheartj\/ehn046","article-title":"Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.","volume":"29","author":"Price","year":"2008","journal-title":"Eur Heart J"},{"key":"R52-7-20210126","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jacc.2011.06.059","article-title":"Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data.","volume":"58","author":"Brar","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R53-7-20210126","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes.","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"R54-7-20210126","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes.","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"R55-7-20210126","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","article-title":"PLATO Investigators. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.","volume":"124","author":"Mahaffey","year":"2011","journal-title":"Circulation"},{"key":"R56-7-20210126","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"PLATO Investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"R57-7-20210126","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"key":"R58-7-20210126","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1111\/j.1538-7836.2010.03923.x","article-title":"Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data.","volume":"8","author":"Sorich","year":"2010","journal-title":"J Thromb Haemost"}],"container-title":["Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HPC.0b013e318292f168","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:44:00Z","timestamp":1620953040000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00132577-201309000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/hpc.0b013e318292f168","relation":{},"ISSN":["1535-282X"],"issn-type":[{"value":"1535-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}